



12,500,000 Results Any time ▾

Consensus statement on dose modifications of antidiabetic ...

www.ijem.in/article.asp?issn=2230-8210;year=2017;volume=21;issue=2;spage=341;epage=354;...

The **treatment of diabetes mellitus (DM)** in **cirrhotic patients** has particular challenges as follows: (1) about half the patients have malnutrition; (2) patients already have advanced **liver disease** when **clinical DM** is diagnosed; (3) most of the oral antidiabetic agents (**ADAs**) are metabolized in the liver; (4) patients often have episodes of hypoglycemia.

Cited by: 3

Author: Kalyan Kumar Gangopadhyay, Parminde...

Publish Year: 2017

[PDF] Consensus Statement on Dose Modifications of ...

https://www.researchgate.net/publication/314961466_Consensus_Statement_on_Dose...

Gangopadhyay and Singh: Consensus statement on dose modifications of **antidiabetic agents in patients with hepatic impairment** 342 **Indian Journal of Endocrinology and Metabolism** | ...

Antidiabetic Agents : Oral Hypoglycemic Agents Flashcards ...

<https://quizlet.com/96193256/antidiabetic-agents-oral-hypoglycemic-agents-flash-cards> ▾

Antidiabetic **Agents** : Oral Hypoglycemic **Agents**. STUDY. PLAY. ... >More common: Can be severe, particularly in elderly with **impaired hepatic** or renal functions who are taking LONGER acting sulfonylureas (chlorpropamide, glimepiride) ... **-Drugs** have MINIMAL renal excretion thus useful in **patients** with **impaired** renal function >NOT safe in **hepatic** ...

Antidiabetic Drugs Flashcards | Quizlet

<https://quizlet.com/261256314/antidiabetic-drugs-flash-cards> ▾

Antidiabetic **Drugs**. A group of disorders characterized by elevated blood glucose associated with absent or inadequate pancreatic insulin secretion, with or without concurrent **impairment** of insulin action. Complications of diabetic - Stroke - Heart attack - Kidney disease - Eye Disease - Nerve Damage.

Nateglinide (Professional Patient Advice) - Drugs.com

<https://www.drugs.com/ppa/nateglinide.html> ▾

Apr 03, 2019 · Special Populations: **Hepatic Function Impairment**. C max increased 37% and AUC increased 30% in patients with **mild hepatic insufficiency**. Use: Labeled Indications. **Diabetes mellitus**, type 2: **Treatment** of adults with type 2 **diabetes mellitus** as an adjunct to diet and

Related searches

levels of hepatic impairment

hepatic impairment **study**

hepatic impairment **labs**

severe hepatic impairment

hepatic impairment **guidelines**

hepatic impairment **fda guidance**

symptoms of hepatic impairment

mild hepatic impairment **definition**

Name of Journal: *World Journal of Meta-Analysis*

Manuscript NO: 49946

Manuscript Type: REVIEW

Antidiabetic agents in patients with hepatic impairment

Papazafiropoulou A *et al.* Antidiabetic agents in patients with HI

Athanasia Papazafiropoulou, Andreas Melidonis

Abstract

Chronic liver disease (CLD) often coexists with type 2 diabetes mellitus, making diabetes management a challenge to the clinician. It is well known that liver is the major site of drug metabolism, and, therefore, its impairment affects hepatic metabolism of many antidiabetic agents. Furthermore, patients with CLD have serious comorbidities such as impaired renal function, hypoalbuminemia, lactic acidosis, hypoglycemia and malnutrition, making

1

Match Overview

Match Number	Source	Words	Similarity
1	Internet crawled on 05-Feb-2019 orbi.uliege.be	69 words	2%
2	Internet crawled on 12-Aug-2019 link.springer.com	23 words	1%
3	Internet crawled on 15-Sep-2016 ftp.palgrave-journals.com	19 words	1%
4	Internet crawled on 04-Jun-2010 www.medicines.org.uk	15 words	<1%
5	Internet crawled on 05-May-2016 hepatmon.com	15 words	<1%
6	Crossref Sanjay Kalra, Ashok Kumar Das, Rakesh Kumar Sahay, Ma nash Pratim Baruah et al. "Consensus Recommendation ...	14 words	<1%
7	Internet crawled on 31-May-2016 hepatitisnewdrugs.blogspot.com	13 words	<1%
8	Internet crawled on 08-Jul-2019 academic.oup.com	13 words	<1%
9	Crossref Damayanthi Devineni, David Polidori. "Clinical Pharmacoki netic, Pharmacodynamic, and Drug-Drug Interaction Pro ...	13 words	<1%
10	Internet crawled on 17-Jun-2016 spectrum.diabetesjournals.org	12 words	<1%



All

Images

Videos

翻译成中文

关闭取词

13,000,000 Results

Any time ▾

Consensus statement on dose modifications of antidiabetic ...

www.ijem.in/article.asp?issn=2230-8210;year=2017;volume=21;issue=2;spage=341;epage=354;...

The treatment of **diabetes mellitus (DM)** in **cirrhotic patients** has particular challenges as follows: (1) about half the patients have malnutrition; (2) patients already have advanced **liver disease** when **clinical DM** is diagnosed; (3) most of the oral antidiabetic agents (**ADAs**) are metabolized in the liver; (4) patients often have episodes of hypoglycemia.

Cited by: 4

Author: Kalyan Kumar Gangopadhyay, Parminder...

Publish Year: 2017

Consensus Statement on Dose Modifications of Antidiabetic ...

https://www.researchgate.net/publication/314961466_Consensus_Statement_on_Dose...

Consensus Statement on Dose Modifications of Antidiabetic **Agents** in **Patients** with **Hepatic Impairment** Article (PDF Available) · March 2017 with 86 Reads DOI: 10.4103/ijem.IJEM_512_16

[PDF] Consensus Statement on Dose Modifications of ...

https://www.researchgate.net/publication/314961466_Consensus_Statement_on_Dose...

Gangopadhyay and Singh: Consensus statement on dose modifications of **antidiabetic agents** in patients with hepatic impairment 342 *Indian Journal of Endocrinology and Metabolism* ; ...

Antidiabetic Agents : Oral Hypoglycemic Agents Flashcards ...

<https://quizlet.com/96193256/antidiabetic-agents-oral-hypoglycemic-agents-flash-cards> ▾

Antidiabetic Agents : Oral Hypoglycemic Agents. To control **hyperglycemia** in type-II DM (not in type I DM) **patients** who CANNOT achieve appropriate control with changes in diet/exercise. -The first-line **drug** prescribed for **treatment** of type II DM. >Converts dietary starch...

Alogliptin (Professional Patient Advice) - Drugs.com

<https://www.drugs.com/ppa/alogliptin.html> ▾

Baseline liver function tests (serum transaminases) are recommended to rule out underlying liver diseases. Use with caution in patients with **abnormal serum transaminases**. Monitor and promptly evaluate **serum transaminase** levels in patients with symptoms of hepatic injury (eg, **fatigue**, **anorexia**, **jaundice**, **dark urine**, and/or **abdominal pain**).

Drug class: dipeptidyl peptidase 4 inhibitors